Bladder Urothelial Carcinoma — Trials

Bladder Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

138 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 60
Recruiting: 23
Ph III recruiting: 3
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: 47.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (21)

clinicaltrialsPublishedShowing 1–13 of 13 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04940299	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	active not recruiting	Phase 2	35	M.D. Anderson Cancer CenterOTHER	1	Sep 16, 2026	clinicaltrials
NCT00365157	Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction	active not recruiting	Phase 1 / Phase 2	171	National Cancer Institute (NCI)NIH	1	Sep 9, 2026